“Special Moment for the Industry”: Executive Foresees Advancements with Anvisa's Review

During the Brazilian Medicinal Cannabis Congress 2025, one of the central themes in the corridors and panels was the revision of RDC 327 by the National Health Surveillance Agency (Anvisa). Gustavo Palhares, CEO of Ease Labs, a pioneering pharmaceutical company in the sector, assessed the current scenario as a watershed moment for the market and for patient safety in Brazil.

For the executive, the recent public consultation, which received over 1,400 contributions, reinforces the importance of social participation in shaping the regulations. "I believe that these discussions on regulatory changes are a very important environment for all sectors of society to voice their opinions regarding this regulatory evolution," stated Palhares.

Flexibility with Safety

One of the highlights of the regulatory discussion is the potential change in the risk classification of cannabis-based products. For Ease Labs, science already provides sufficient support for significant advancements, especially for products with low levels of tetrahydrocannabinol (THC).

"In our view, Anvisa is well aware that cannabis products, especially those with up to 0.2% THC, have proven to be safe for treatment," explained the CEO.

This perception of safety opens doors for practical changes in the dispensing of medications. Palhares is optimistic about the proposal to change the prescription requirement, moving from a prescription notification A (black stripe) to a special control prescription (red stripe), in addition to a "possible inclusion of other prescriber classes."

Focus on Technical Rigor

Despite the prospect of increased access, Palhares warns that market maturity will come with greater demands. According to him, the regulatory agency is likely to "raise the bar" in terms of the technical rigor required of companies.

"In our view, the agency is very focused on patient safety," pointed out Palhares. "Anvisa's role is clearly to try to build a regulatory framework that ensures the safety of the Brazilian population."

A Special Moment for the Industry

Beyond the regulations, the atmosphere at the Congress was optimistic about business prospects. The executive described the current stage of the Brazilian market as a "very special moment," citing the opening of new sales channels and product possibilities. Palhares also highlighted the relevance of the event organized by Sechat for the maturation of the medical cannabis ecosystem.

The Brazilian Medicinal Cannabis Congress is establishing itself as the main stage for scientific and regulatory debates in Latin America. Following the success of the 2025 edition, the organization is already preparing for next year's event.

For healthcare professionals, entrepreneurs, and investors looking to secure a presence in discussions that will shape the future of the market, slots for the 2026 edition are now open.

For more information and registrations, visit: congressocannabis.com.br